FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study

Table 3 Treatment-related adverse events due to the chemotherapy regimen, n (%)

	FOLFIRINOX (n = 86)	Gem + nabPTX (n = 81)	P value
Hematologic adverse event
Grade ≥ 3 Anemia	17 (19.8)	12 (14.8)	0.398
Grade ≥ 3 Thrombocytopenia	7 (8.1)	5 (6.2)	0.623
Grade ≥ 3 Neutropenia	64 (74.4)	38 (46.9)	< 0.001
Febrile neutropenia	22 (25.6)	13 (16.0)	0.130
Administration of G-CSF	66 (76.7)	15 (18.5)	< 0.001
Neurologic adverse event
Peripheral neuropathy	16 (18.6)	46 (56.8)	< 0.001
Grade ≥ 3 neuropathy	3 (3.5)	15 (18.5)	0.002
Median time to onset-days (range)	120 (15-278)	73.5 (17-284)	0.051
Gastrointestinal adverse event
Nausea/Vomiting	43 (50.0)	17 (21.0)	< 0.001
Diarrhea	15 (17.4)	12 (14.8)	0.645
Grade ≥ 3 adverse events	39 (45.3)	16 (19.8)	< 0.001
General weakness	30 (34.9)	40 (49.4)	0.058
Dermatologic adverse event	12 (14.0)	34 (42.0)	< 0.001

G-CSF, granulocyte-colony stimulating factor; Gem + nabPTX: Gemcitabine plus nab-paclitaxel.